31. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Issue 2 (12th July 2020) Authors: Motzer, Robert J; Escudier, Bernard; McDermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthélémy, Philippe; Hammers, Hans J; George, Saby; Grünwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K; Rini... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
32. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Issue 2 (12th July 2020) Authors: Motzer, Robert J; Escudier, Bernard; McDermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthélémy, Philippe; Hammers, Hans J; George, Saby; Grünwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K; Rini... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
33. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Issue 2 (12th July 2020) Authors: Motzer, Robert J; Escudier, Bernard; McDermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthélémy, Philippe; Hammers, Hans J; George, Saby; Grünwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K; Rini... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
34. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Issue 2 (12th July 2020) Authors: Motzer, Robert J; Escudier, Bernard; McDermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthélémy, Philippe; Hammers, Hans J; George, Saby; Grünwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K; Rini... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
35. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Issue 2 (12th July 2020) Authors: Motzer, Robert J; Escudier, Bernard; McDermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthélémy, Philippe; Hammers, Hans J; George, Saby; Grünwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K; Rini... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
36. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Issue 2 (12th July 2020) Authors: Motzer, Robert J; Escudier, Bernard; McDermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthélémy, Philippe; Hammers, Hans J; George, Saby; Grünwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K; Rini... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
37. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Issue 2 (12th July 2020) Authors: Motzer, Robert J; Escudier, Bernard; McDermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthélémy, Philippe; Hammers, Hans J; George, Saby; Grünwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K; Rini... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
38. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Issue 2 (12th July 2020) Authors: Motzer, Robert J; Escudier, Bernard; McDermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthélémy, Philippe; Hammers, Hans J; George, Saby; Grünwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K; Rini... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
39. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. Issue 7 (3rd July 2022) Authors: Viray, Hollis; McDermott, David F; Einstein, David J Journal: Expert review of anticancer therapy Issue: Volume 22:Issue 7(2022) Page Start: 695 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
40. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Issue 1 (January 2020) Authors: Rini, Brian I; Pal, Sumanta K; Escudier, Bernard J; Atkins, Michael B; Hutson, Thomas E; Porta, Camillo; Verzoni, Elena; Needle, Michael N; McDermott, David F Journal: Lancet oncology Issue: Volume 21:Issue 1(2020) Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗